Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.

Ubrelvy (ubrogepant) is a prescription drug that treats migraine episodes. This drug can interact with certain other medications and some supplements. For example, Ubrelvy can interact with ...

ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...

People suffering from headaches, even if they are relatively mild, may be more prone to committing suicide, a study warns.

ABBV's fourth-quarter earnings and sales beat estimates. Management raises the 2027 forecast for newer immunology drugs to ...

Ubrelvy (ubrogepant) is a prescription drug that’s used to treat migraine episodes. The drug comes as a tablet that you swallow. It’s usually taken as needed. Ubrelvy is prescribed for adults ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary ...

AbbVie Inc. (NYSE:ABBV) shares are trading higher on Friday. The company reported fourth-quarter adjusted earnings per share ...

AbbVie reported strong Q4 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care. Click here to find out why ...

Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being ...

Other drugs in AbbVie's lineup, including Botox, migraine therapies Qulipta and Ubrelvy, cancer drug Venclexta, and antipsychotic medication Vrayalar, are also delivering strong sales growth.